IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v16y2019i16p2966-d258606.html
   My bibliography  Save this article

Indirect Costs of Rheumatoid Arthritis Depending on Type of Treatment—A Systematic Literature Review

Author

Listed:
  • Bogdan Batko

    (Department of Rheumatology, J. Dietl Specialist Hospital, Skarbowa 1 St, 31-121 Cracow, Poland)

  • Paulina Rolska-Wójcik

    (HTA Consulting, Starowislna 17/3 St, 31-038 Cracow, Poland)

  • Magdalena Władysiuk

    (HTA Consulting, Starowislna 17/3 St, 31-038 Cracow, Poland)

Abstract

The economic burden of rheumatoid arthritis (RA) on society is high. Disease-modifying antirheumatic drugs (DMARDs) are the cornerstone of therapy. Biological DMARDs are reported to prevent disability and improve quality of life, thus reducing indirect RA costs. We systematically reviewed studies on the relationship between RA and indirect costs comparing biological treatment with standard care. Studies, economic analyses, and systematic reviews published until October 2018 through a MEDLINE search were included. A total of 153 non-duplicate citations were identified, 92 (60%) were excluded as they did not meet pre-defined inclusion criteria. Sixty-one articles were included, 17 of them (28%) were reviews. After full-text review, 28 articles were included, 11 of them were reviews. Costs associated with productivity loss are substantial; in several cases, they may represent over 50% of the total. The most common method of estimation is the Human Capital method. However, certain heterogeneity is observed in the method of estimating, as well as in the resultant figures. Data from included trials indicate that biological therapy is associated with improved labor force participation despite an illness, in which the natural course of disease is defined by progressive work impairment. Use of biological DMARDs may lead to significant indirect cost benefits to society.

Suggested Citation

  • Bogdan Batko & Paulina Rolska-Wójcik & Magdalena Władysiuk, 2019. "Indirect Costs of Rheumatoid Arthritis Depending on Type of Treatment—A Systematic Literature Review," IJERPH, MDPI, vol. 16(16), pages 1-16, August.
    • Handle: RePEc:gam:jijerp:v:16:y:2019:i:16:p:2966-:d:258606
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/16/16/2966/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/16/16/2966/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. J. Smolen & D. Aletaha, 2008. "The burden of rheumatoid arthritis and access to treatment: a medical overview," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 39-47, January.
    2. Sonja Merkesdal & Timm Kirchhoff & Diane Wolka & Gunter Ladinek & Adrian Kielhorn & Andrea Rubbert-Roth, 2010. "Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(1), pages 95-104, February.
    3. Deng-Ho Yang & Jing-Yang Huang & Jeng-Yuan Chiou & James Cheng-Chung Wei, 2018. "Analysis of Socioeconomic Status in the Patients with Rheumatoid Arthritis," IJERPH, MDPI, vol. 15(6), pages 1-12, June.
    4. B. Jönsson & G. Kobelt & J. Smolen, 2008. "The burden of rheumatoid arthritis and access to treatment: uptake of new therapies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 61-86, January.
    5. J. Lundkvist & F. Kastäng & G. Kobelt, 2008. "The burden of rheumatoid arthritis and access to treatment: health burden and costs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 49-60, January.
    6. J. Lundqvist & F. Kastäng & G. Kobelt & B. Jönsson, 2008. "The burden of rheumatoid arthritis and access to treatment: determinants of access," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 87-93, January.
    7. G. Kobelt & B. Jönsson, 2008. "The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 95-106, January.
    8. Deirdre Connolly & Clodagh Fitzpatrick & Lynn O’Toole & Michele Doran & Finbar O’Shea, 2015. "Impact of Fatigue in Rheumatic Diseases in the Work Environment: A Qualitative Study," IJERPH, MDPI, vol. 12(11), pages 1-16, October.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Evo Alemao & Maiwenn J Al & Annelies A Boonen & Matthew D Stevenson & Suzanne M M Verstappen & Kaleb Michaud & Michael E Weinblatt & Maureen P M H Rutten-van Mölken, 2018. "Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-18, October.
    2. Kurt Brekke & Dag Dalen & Tor Holmås, 2014. "Diffusion of pharmaceuticals: cross-country evidence of anti-TNF drugs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 937-951, December.
    3. Márta Péntek & Gyula Poór & Piotr Wiland & Martina Olejárová & Marek Brzosko & Catalin Codreanu & Nóra Brodszky & László Gulácsi, 2014. "Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 35-43, May.
    4. Ulf Persson, 2012. "Value Based Pricing in Sweden: Lessons for Design?," Seminar Briefing 000141, Office of Health Economics.
    5. Benjamin Birkner & Jürgen Rech & Tom Stargardt, 2020. "Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis," PLOS ONE, Public Library of Science, vol. 15(1), pages 1-17, January.
    6. Azucena Pedraz-Marcos & Ana María Palmar-Santos & Claire Anne Hale & Juan Zarco-Colón & Milagros Ramasco-Gutiérrez & Eva García-Perea & Teresa Velasco-Ripoll & Josefina Martín-Alarcón & Nuria Sa, 2020. "Living With Rheumatoid Arthritis in Spain: A Qualitative Study of Patient Experience and the Role of Health Professionals," Clinical Nursing Research, , vol. 29(8), pages 551-560, November.
    7. Karine Chevreul & Georges Haour & Sandy Lucier & Stephanie Harvard & Marie-Laure Laroche & Xavier Mariette & Alain Saraux & Isabelle Durand-Zaleski & Francis Guillemin & Bruno Fautrel, 2014. "Evolution of Direct Costs in the First Years of Rheumatoid Arthritis: Impact of Early versus Late Biologic Initiation - An Economic Analysis Based on the ESPOIR Cohort," PLOS ONE, Public Library of Science, vol. 9(5), pages 1-9, May.
    8. Márta Péntek & László Gulácsi & Bernadette Rojkovich & Valentin Brodszky & Job Exel & Werner Brouwer, 2014. "Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 83-92, May.
    9. László Gulácsi, 2010. "Future challenges for health economics and health technology assessment of biological drugs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(3), pages 235-238, June.
    10. Sonja Merkesdal & Timm Kirchhoff & Diane Wolka & Gunter Ladinek & Adrian Kielhorn & Andrea Rubbert-Roth, 2010. "Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(1), pages 95-104, February.
    11. Michael Drummond & Bengt Jönsson & Frans Rutten & Tom Stargardt, 2011. "Reimbursement of pharmaceuticals: reference pricing versus health technology assessment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(3), pages 263-271, June.
    12. P. Laires & F. Exposto & R. Mesquita & A. Martins & L. Cunha-Miranda & J. Fonseca, 2013. "Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 875-885, December.
    13. Paul Gavaza & Karen Rascati & Abiola Oladapo & Star Khoza, 2012. "The State of Health Economic Research in South Africa," PharmacoEconomics, Springer, vol. 30(10), pages 925-940, October.
    14. Jaana T Joensuu & Saara Huoponen & Kalle J Aaltonen & Yrjö T Konttinen & Dan Nordström & Marja Blom, 2015. "The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-27, March.
    15. Stefan Scholz & Thomas Mittendorf, 2014. "Modeling rheumatoid arthritis using different techniques - a review of model construction and results," Health Economics Review, Springer, vol. 4(1), pages 1-16, December.
    16. Krol, Marieke & Brouwer, Werner, 2015. "Unpaid work in health economic evaluations," Social Science & Medicine, Elsevier, vol. 144(C), pages 127-137.
    17. Chaima Louati & Yosra Mouelhi & Bernard Kabuth & Céline Clément, 2022. "“ Without Them, I Would Never Have Been Able to Carry on ” Levers for the Sustained Employment of Patients with Chronic Inflammatory Arthritis: A French Qualitative Study," IJERPH, MDPI, vol. 19(21), pages 1-11, November.
    18. Wojciech Tański & Krzysztof Dudek & Tomasz Adamowski, 2022. "Work Ability and Quality of Life in Patients with Rheumatoid Arthritis," IJERPH, MDPI, vol. 19(20), pages 1-18, October.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:16:y:2019:i:16:p:2966-:d:258606. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.